Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

• Conditions: Lymphomas

• Registration Number: NCT01828008
• Lead Sponsor: Han weidong

Brief Summary

To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed Description

Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Study Timeline

• Status Verified: 2013-01
• Study Start: 2013-04
• Study First Submitted: 2013-04-06
• Study First Submitted QC: 2013-04-09
• Last Update Submitted: 2013-04-09
• Study First Posted: 2013-04-10
• Last Update Posted: 2013-04-10
• Primary Completion: 2015-05
• Study Completion: 2015-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion Criteria

• to refuse the therapy and need not tolerate the therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
disease free survival	5 years